MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY

• 1. 使用嵌合抗原受体（CARS）的胎盘样硫酸软骨素的免疫治疗靶向和使用具有分割蛋白结合系统的CARS的癌症的免疫治疗靶向 [P] . 中国专利： CN107438625A . 2017-12-05
• 2. 用于癌症免疫治疗的抗CLL1特异性单链嵌合抗原受体(scCAR) [P] . 中国专利： CN107406516B . 2021.11.23
• 3. MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY [P] . 世界知识产权组织专利： WO2018175279A2 . 2018-09-27

  机译： 减轻Fc-Fc受体在癌症免疫治疗中的相互作用

• 4. RHAMM, A CO-RECEPTOR AND ITS INTERACTIONS WITH OTHER RECEPTORS IN CANCER CELL MOTILITY AND THE IDENTIFICATION OF CANCER PROGNITOR CELL POPULATIONS [P] . 美国专利： US2016130352A1 . 2016-05-12

  机译： RHAMM，一种共同受体及其与其他受体在肿瘤细胞运动中的相互作用以及对肿瘤细胞数量的识别

• 5. Rhamm, a Co-Receptor and Its Interactions with Other Receptors in Cancer Cell Motility and the Identification of Cancer Prognitor Cell Populations [P] . 美国专利： US2010062000A1 . 2010-03-11

  机译： Rhamm，在癌细胞运动中的辅助受体及其与其他受体的相互作用以及癌前体细胞群的鉴定

• 1. Volume transmission and receptor-receptor interactions in heteroreceptor complexes:understanding the role of new concepts for brain communication [J] . Kjell Fuxe, Dasiel O Borroto-Escuela 中国神经再生研究（英文版） . 2016,第008期
• 2. Computational Study of the Interactions between Antimalarial Chemotherapies with Folate Pathway Receptors and Telomerase Reverse Transcriptase [J] . Djogang Lucie Karelle, Forlemu Neville, Emadak Alphonse, 计算化学（英文） . 2021,第003期
• 3. Bridging immunogenicity assays for IgG4 therapeutics: mitigating interference from Fc-Fc interactions [J] . Partridge Michael A., Vijayam Uma, Karayusuf Elif Kabuloglu, Bioanalysis . 2017,第9期
• 4. Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas [J] . Jain Salvia, Van Scoyk Alexandria, Morgan Elizabeth A., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期
• 5. EphrinA1–EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model [J] . Manish Tandon, Sai V. Vemula, Anurag Sharma, The journal of gene medicine . 2012,第2期
• 6. HER1 THERAPEUTIC CANCER VACCINE: AN ACTIVE IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH TUMORS EXPRESSING THE RECEPTOR OF EPIDERMAL GROWTH FACTOR (EGF-R) [C] . Eduardo Suarez, Belinda Sanchez, Zaima Mazorra, Conference on vaccine technology VI . 2018
• 7. Defining the Role of Fc-Fc Gamma Receptor Interactions in the Anti-Tumor Function of Anti-CD137 Monoclonal Antibody Therapy. [D] . Sallin, MIchelle. 2013
• 8. Divergent Requirement of Fc-Fcγ Receptor Interactions for In Vivo Protection against Influenza Viruses by Two Pan-H5 Hemagglutinin Antibodies [O] . Shuangshuang Wang, Huanhuan Ren, Wenbo Jiang, 2017
• 9. The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy? [O] . Jiji V. D. Attia, Charlotte E. Dessens, Ricky van de Water, 2020

• 1. Cancer immunotherapy by targeting immune checkpoint receptors [J] . Noah Isakov . 世界免疫学杂志 . 2018,第1期
• 2. Altered expression of stromal interaction molecule(STIM)-calcium release-activated calcium channel protein(ORAI) and inositol1,4,5-trisphosphate receptors(IP_3Rs)in cancer:will they become a new battlefield for oncotherapy? [J] . Jing Wen ,Ying-Cheng Huang ,Huan-Huan Xiu . 癌症 . 2016,第5期
• 3. Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report [J] . Ding Li ,Cheng Cheng ,Wen-Ping Song . 世界临床病例杂志 . 2021,第036期
• 4. 中医药在减轻癌症放化疗毒副反应中的研究进展 [C] . 张钱钱 ,刘志宏 ,宋洪涛 . 2012转化医学与中药现代化高峰论坛 . 2012
• 5. 吗啡预处理经由ERK通路调控受体相互作用蛋白减轻大鼠全心缺血再灌注损伤的作用机制 [A] . 黄俊 . 2018